Pre-made Panitumumab biosimilar ( Whole mAb, anti-EGFR therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-425
Anti-EGFR therapeutic antibody (Pre-made Panitumumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-EGFR therapeutic antibody (Pre-made Panitumumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||5sx5:HL:JK/5sx4:HL:JI|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Amgen;Grupo Espanol Multidisciplinario del Cancer Digestivo;Netherlands Cancer Institute;Novartis;Takeda;University of Texas M. D. Anderson Cancer Center;Wissenschaftlicher Service Pharma|
|Conditions Approved||Colorectal cancer|
|Conditions Active||Anal cancer;Bladder cancer;Breast cancer;Gastric cancer;Neuroendocrine tumours;Oesophageal cancer;Rectal cancer|
|Conditions Discontinued||Head and neck cancer;Malignant melanoma;Prostate cancer;Renal cell carcinoma;Solid tumours|
|Development Tech||Abgenix XenoMouse|